glp·helper
glphelper.com/tirzepatide/mississippi/southaven
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022 (Mounjaro) · November 2023 (Zepbound)Rx · Subcutaneous injection · Once weekly

Tirzepatide® providers &
prescriptions in Southaven, MS

Verified Tirzepatide providers in Southaven, MS. Checked against the NPI registry, never ranked by who pays us.[7]

city providers
34
as of today
§ 02Provider directory: Mississippi
34 of 34 shown

Find a Tirzepatide provider in Mississippi.

Every entry is checked against the federal NPI registry. We do not accept payment for placement.

Filter →
Type
Provider
City
Insurance / phone
Browse by Mississippi city · /tirzepatide/mississippi/{city}
§ 03Getting Tirzepatide in Southaven
34 providers · Southaven, MS

How to get Tirzepatide in Southaven.

34 GLP-1 prescribers and 5 local resource types are on record for Southaven, plus 3 nearby towns in the directory.

Prescribers in Southaven
34 prescribers
34 GLP-1 prescribers in Southaven, most listed as Internal Medicine (12), Family Medicine (11) and Internal Medicine, Endocrinology, Diabetes & Metabolism (8). Any Mississippi-licensed physician, nurse practitioner, or PA can prescribe Tirzepatide, over video or in person. The nearest towns on record are Tupelo (30 providers), Jackson (38 providers) and Meridian (30 providers).
Around the prescription in Southaven
5 listed nearby
16 dietitians, 6 gyms, 6 fitness clubs, 6 physiotherapists and 3 places to move are on record near Southaven.
Medicaid (weight loss)
Covered
As of April 2026, Mississippi Medicaid covers GLP-1s for weight loss, usually with prior authorization and BMI criteria, on top of the standard diabetes coverage. Employer and private plans vary; coverage is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Mississippi’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Mounjaro and Zepbound. It acts on two gut-hormone pathways, GIP and GLP-1.

Tirzepatide is a once-weekly injection sold by Eli Lilly as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). It is the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one, which is associated with greater average weight loss than single GLP-1 agonists.[2][3]

In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% on placebo. In the SURPASS-2 head-to-head diabetes trial, tirzepatide produced larger HbA1c and weight reductions than semaglutide 1 mg.[1]

At a glanceMultiple (brand-specific)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022 (Mounjaro) · November 2023 (Zepbound)
Approved use
Type 2 diabetes (Mounjaro) · chronic weight management (Zepbound)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Southaven

Southaven, Mississippi has a population of 54,648 people. The adult obesity rate in Southaven is an age-adjusted estimate of 37.1%, 3.3 percentage points below the Mississippi state rate of 40.4%. Diagnosed diabetes reaches 11.6% of adults in Southaven. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 28.1% of adults in Southaven.

of Southaven adults have obesity
37.1%
diagnosed diabetes
11.6%
no regular physical activity
28.1%

Age-adjusted estimates for Southaven, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight losswhy facial fat loss happens
§ 05Support around Tirzepatide in Southaven
6 dietitians

The prescription is one part. Here is the rest, in Southaven.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Southaven, MS, ordered as the registry lists them, never by who pays us.

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Lexann Bursi, RD, LDN
RD
Registered dietitian
9215 Millbranch Rd
Call 662-548-8075NPI 1518268705
Shirley Davis, RDN LD
RD
Registered dietitian
6856 Cobblestone Blvd
Call 888-416-0008NPI 1255758504
John Dudley, RD
RD
Registered dietitian
6856 Cobblestone Blvd
Call 888-416-0008NPI 1083025944
Judy Galloway, RD, LD, LDN, CDE
RD
Registered dietitian
7601 Southcrest Parkway
Call 662-772-3183NPI 1922336387
Kimberly Kilpatrick, RD, LD
RD
Registered dietitian
7601 Southcrest Pkwy
Call 662-772-3199NPI 1740450410
Andrea Komm, MS, RD, LD
RD
Registered dietitian
7601 Southcrest Pkwy
Call 662-772-3186NPI 1700057031

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

Planet Fitness
GYM
4.5 on Google · 640 reviews
4126 Elvis Presley Blvd
Website
Total Fitness Kickboxing - Southaven, MS
GYM
5.0 on Google · 407 reviews
5915 Getwell Rd Ste 1
Website
CLUB4 Fitness Horn Lake
GYM
4.4 on Google · 263 reviews
3828 Goodman Rd W
Website
Planet Fitness
GYM
4.7 on Google · 174 reviews
3031 Goodman Rd W
Website
Crunch Fitness - Southaven
GYM
3.5 on Google · 165 reviews
570 Main St
Website
Edge Fitness LLC
GYM
4.1 on Google · 78 reviews
4935 Pepper Chase Dr
Website
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURMOUNT weight-management program and the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) across 72 weeks. Mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. A majority of patients on the higher doses lost ≥20% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (15 mg)
−20.9%
SURMOUNT-1, 72 wk vs −3.1% placebo[2]
Mean weight change (5 mg)
−15.0%
SURMOUNT-1, 72 wk[2]
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average tirzepatide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Zepbound (no insurance)
$1,000 to $1,300
per month
Brand-name retail; Lilly self-pay vials lower for some doses[6]
Cash, Mounjaro (no insurance)
$1,000 to $1,200
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Zepbound is on-label but frequently requires PA
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Tirzepatide providers in Mississippi

NPI-verified Tirzepatide (tirzepatide) prescribers and clinics, never ranked by who pays us.

Tirzepatide in other states

Find NPI-verified Tirzepatide (tirzepatide) doctors, clinics, and pharmacies in the states we cover, never ranked by who pays us.

Related GLP-1 research
§ 09Frequently asked: Tirzepatide in Mississippi

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Tirzepatide is the active molecule in both Eli Lilly products. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. They are the same drug with different approved indications, and insurers treat them as separate products.[1]